June 29 (Reuters) – The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron among seven companies for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC reported on Monday, citing an FDA spokesperson.
Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin will participate in the FDA’s PreCheck pilot program, the report said, citing FDA’s Benjamin Nichols.
The program will allow regulators to start reviewing new manufacturing facilities while they are being built to catch and correct any issues, which the FDA estimates could save companies up to 14 months, CNBC’s report said.
The U.S. Department of Health and Human Services, which oversees the FDA, did not immediately respond to a Reuters request for comment.
(Reporting by Puyaan Singh in Bengaluru; Editing by Sahal Muhammed)
Comments